IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial

作者：Shengli Xue, Meijing Liu, Chongsheng Qian, Suning Chen, Hui-Ying Qiu, Liqing Kang, Haiping Dai, Wenjie Gong, Liyun Chen, Zhen Yao, Mingzhu Xu, Haixia Zhou, Xiaofei Yang, Qian Wu, Xueqing Dou, Jian Zhang, Yin Liu, Qingya Cui, Li Zheng, Yang Xu, Man Qiao, Tongtong Zhang, Jingwen Tan, Nan Xu, Minghao Li, Yu Zhou, Xiaoyan Lou, Wei Wang, Hongjia Zhu, Qin Lu, Lei Yu, Xiaowen Tang, Depei Wu · 发表于：Blood Cancer Journal · 年份：2025 · DOI：10.1038/s41408-025-01397-4 · 被引用次数：3 · 研究领域：CAR-T cell therapy research、Virus-based gene therapy research、Viral Infectious Diseases and Gene Expression in Insects

CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell therapy is a revolutionary immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), with 60%–80% response rates [ 1 ]. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain life-threatening toxicities in CAR-T therapy, constraining its wider clinical adoption [ 1 , 2 , 3 ]. In the ZUMA-3 study of KTE-X19 for r/r B-ALL, 93% of patients developed CRS, with 31% graded ≥3, and 78% developed ICANS, with 38% being grade 3 or worse [ 1 ].